Molecular Basis for Redox Activation of Epidermal Growth Factor Receptor Kinase

Cell Chemical Biology

Volumn 23, Issue 7, 2016, Pages 837-848

  Truong, Thu H ^a,b   Ung, Peter Man Un ^c   Palde, Prakash B ^b   Paulsen, Candice E ^b   Schlessinger, Avner ^c   Carroll, Kate S ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ALANINE; ARGININE; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUTATHIONE TRANSFERASE; HYDROGEN; HYDROGEN PEROXIDE; LYSINE; OXYGEN; EGFR PROTEIN, HUMAN; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ARTICLE; AUTOPHOSPHORYLATION; BINDING AFFINITY; CATALYSIS; CATALYTIC EFFICIENCY; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENETIC TRANSFECTION; HELA CELL LINE; HUMAN; HUMAN CELL; HYDROGEN BOND; IMMUNOPRECIPITATION; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MOLECULAR DYNAMICS; MOLECULAR MODEL; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PEPTIDE MAPPING; POINT MUTATION; PROTEIN EXPRESSION; RATE CONSTANT; STATIC ELECTRICITY; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; METABOLISM; MUTATION; STRUCTURE ACTIVITY RELATION; TUMOR CELL CULTURE;

ENZYME ACTIVATION; HUMANS; MOLECULAR DYNAMICS SIMULATION; MUTATION; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 84978715599     PISSN: 24519456     EISSN: 24519448     Source Type: Journal    
DOI: 10.1016/j.chembiol.2016.05.017     Document Type: Article

References (66)

1. Anderson, T.A., Sauer, R.T., Role of an N(cap) residue in determining the stability and operator-binding affinity of Arc repressor. Biophys. Chem. 100 (2003), 341–350.
2. 2 gradients across biomembranes. FEBS Lett. 475 (2000), 121–126.
3. Askoxylakis, V., Millonig, G., Wirkner, U., Schwager, C., Rana, S., Altmann, A., Haberkorn, U., Debus, J., Mueller, S., Huber, P.E., Investigation of tumor hypoxia using a two-enzyme system for in vitro generation of oxygen deficiency. Radiat. Oncol., 6, 2011, 35.
4. Blume-Jensen, P., Hunter, T., Oncogenic kinase signalling. Nature 411 (2001), 355–365.
5. Bogdan, S., Klambt, C., Epidermal growth factor receptor signaling. Curr. Biol. 11 (2001), R292–R295.
6. Brewer, T.F., Garcia, F.J., Onak, C.S., Carroll, K.S., Chang, C.J., Chemical approaches to discovery and study of sources and targets of hydrogen peroxide redox signaling through NADPH oxidase proteins. Ann. Rev. Biochem. 84 (2015), 765–790.
7. Chouchani, E.T., Kazak, L., Jedrychowski, M.P., Lu, G.Z., Erickson, B.K., Szpyt, J., Pierce, K.A., Laznik-Bogoslavski, D., Vetrivelan, R., Clish, C.B., et al. Mitochondrial ROS regulate thermogenic energy expenditure and sulfenylation of UCP1. Nature 532 (2016), 112–116.
8. Cohen, S., Carpenter, G., King, L. Jr., Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J. Biol. Chem. 255 (1980), 4834–4842.
9. Corcoran, A., Cotter, T.G., Redox regulation of protein kinases. FEBS J. 280 (2013), 1944–1965.
10. Dickinson, B.C., Chang, C.J., Chemistry and biology of reactive oxygen species in signaling or stress responses. Nat. Chem. Biol. 7 (2011), 504–511.
11. Dotsey, E.Y., Jung, K.M., Basit, A., Wei, D., Daglian, J., Vacondio, F., Armirotti, A., Mor, M., Piomelli, D., Peroxide-dependent MGL sulfenylation regulates 2-AG-Mediated endocannabinoid signaling in brain neurons. Chem. Biol. 22 (2015), 619–628.
12. Finkel, T., From sulfenylation to sulfhydration: what a thiolate needs to tolerate. Sci. Signal., 5, 2012, pe10.
13. Fraczkiewicz, R., Braun, W., Exact and efficient analytical calculation of the accessible surface areas and their gradients for macromolecules. J. Comp. Chem. 19 (1998), 319–333.
14. Fry, D.W., Bridges, A.J., Denny, W.A., Doherty, A., Greis, K.D., Hicks, J.L., Hook, K.E., Keller, P.R., Leopold, W.R., Loo, J.A., et al. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl. Acad. Sci. USA 95 (1998), 12022–12027.
15. Gajiwala, K.S., Feng, J., Ferre, R., Ryan, K., Brodsky, O., Weinrich, S., Kath, J.C., Stewart, A., Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition. Structure 21 (2013), 209–219.
16. Garcia, F.J., Carroll, K.S., Redox-based probes as tools to monitor oxidized protein tyrosine phosphatases in living cells. Eur. J. Med. Chem. 88 (2014), 28–33.
17. Gould, N.S., Evans, P., Martinez-Acedo, P., Marino, S.M., Gladyshev, V.N., Carroll, K.S., Ischiropoulos, H., Site-specific proteomic mapping identifies selectively modified regulatory cysteine residues in functionally distinct protein networks. Chem. Biol. 22 (2015), 965–975.
18. Gupta, V., Carroll, K.S., Sulfenic acid chemistry, detection and cellular lifetime. Biochim. Biophys. Acta 1840 (2014), 847–875.
19. Gupta, V., Carroll, K.S., Profiling the reactivity of cyclic C-nucleophiles towards electrophilic sulfur in cysteine sulfenic acid. Chem. Sci. 7 (2016), 400–415.
20. Gupta, V., Carroll, K.S., Rational design of reversible and irreversible cysteine sulfenic acid-targeted linear C-nucleophiles. Chem. Commun. (Camb) 52 (2016), 3414–3417.
21. Haque, A., Andersen, J.N., Salmeen, A., Barford, D., Tonks, N.K., Conformation-sensing antibodies stabilize the oxidized form of PTP1B and inhibit its phosphatase activity. Cell 147 (2011), 185–198.
22. Heppner, D.E., van der Vliet, A., Redox-dependent regulation of epidermal growth factor receptor signaling. Redox Biol. 8 (2015), 24–27.
23. Holmstrom, K.M., Finkel, T., Cellular mechanisms and physiological consequences of redox-dependent signalling. Nat. Rev. Mol. Cell Biol. 15 (2014), 411–421.
24. Hubbard, S.R., EGF receptor inhibition: attacks on multiple fronts. Cancer Cell 7 (2005), 287–288.
25. Johnson, B.E., Janne, P.A., Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res. 65 (2005), 7525–7529.
26. Kobayashi, S., Boggon, T.J., Dayaram, T., Janne, P.A., Kocher, O., Meyerson, M., Johnson, B.E., Eck, M.J., Tenen, D.G., Halmos, B., EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352 (2005), 786–792.
27. Leonard, S.E., Garcia, F.J., Goodsell, D.S., Carroll, K.S., Redox-based probes for protein tyrosine phosphatases. Angew. Chem. Int. Ed. Engl. 50 (2011), 4423–4427.
28. Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L.R., Padera, R.F., Shapiro, G.I., Baum, A., Himmelsbach, F., et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27 (2008), 4702–4711.
29. Liu, Q., Sabnis, Y., Zhao, Z., Zhang, T., Buhrlage, S.J., Jones, L.H., Gray, N.S., Developing irreversible inhibitors of the protein kinase cysteinome. Chem. Biol. 20 (2013), 146–159.
30. Lo Conte, M., Carroll, K.S., Chemoselective ligation of sulfinic acids with aryl-nitroso compounds. Angew. Chem. Int. Ed. Engl. 51 (2012), 6502–6505.
31. Lo Conte, M., Carroll, K.S., The redox biochemistry of protein sulfenylation and sulfinylation. J. Biol. Chem. 288 (2013), 26480–26488.
32. Lo Conte, M., Lin, J., Wilson, M.A., Carroll, K.S., A chemical approach for the detection of protein sulfinylation. ACS Chem. Biol. 10 (2015), 1825–1830.
33. Long, M.J., Tucci, M.A., Benghuzzi, H.A., Human gingival fibroblast cell response to gox/cat. Biomed. Sci. Instrum. 48 (2012), 268–274.
34. Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004), 2129–2139.
35. Meng, T.C., Fukada, T., Tonks, N.K., Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol. Cell 9 (2002), 387–399.
36. Miller, E.W., Tulyathan, O., Isacoff, E.Y., Chang, C.J., Molecular imaging of hydrogen peroxide produced for cell signaling. Nat. Chem. Biol. 3 (2007), 263–267.
37. Millonig, G., Hegedusch, S., Becker, L., Seitz, H.K., Schuppan, D., Mueller, S., Hypoxia-inducible factor 1 alpha under rapid enzymatic hypoxia: cells sense decrements of oxygen but not hypoxia per se. Free Radic. Biol. Med. 46 (2009), 182–191.
38. Miranda, J.J., Position-dependent interactions between cysteine residues and the helix dipole. Protein Sci. 12 (2003), 73–81.
39. Mishina, N.M., Tyurin-Kuzmin, P.A., Markvicheva, K.N., Vorotnikov, A.V., Tkachuk, V.A., Laketa, V., Schultz, C., Lukyanov, S., Belousov, V.V., Does cellular hydrogen peroxide diffuse or act locally?. Antioxid. Redox Signal. 14 (2011), 1–7.
40. Mueller, S., Millonig, G., Waite, G.N., The GOX/CAT system: a novel enzymatic method to independently control hydrogen peroxide and hypoxia in cell culture. Adv. Med. Sci. 54 (2009), 121–135.
41. Paulsen, C.E., Carroll, K.S., Cysteine-mediated redox signaling: chemistry, biology, and tools for discovery. Chem. Rev. 113 (2013), 4633–4679.
42. Paulsen, C.E., Truong, T.H., Garcia, F.J., Homann, A., Gupta, V., Leonard, S.E., Carroll, K.S., Peroxide-dependent sulfenylation of the EGFR catalytic site enhances kinase activity. Nat. Chem. Biol. 8 (2012), 57–64.
43. Penel, S., Hughes, E., Doig, A.J., Side-chain structures in the first turn of the alpha-helix. J. Mol. Biol. 287 (1999), 127–143.
44. Schlessinger, J., Cell signaling by receptor tyrosine kinases. Cell 103 (2000), 211–225.
45. Schwartz, P.A., Kuzmic, P., Solowiej, J., Bergqvist, S., Bolanos, B., Almaden, C., Nagata, A., Ryan, K., Feng, J., Dalvie, D., et al. Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance. Proc. Natl. Acad. Sci. USA 111 (2014), 173–178.
46. Shawver, L.K., Slamon, D., Ullrich, A., Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1 (2002), 117–123.
47. Sies, H., Role of metabolic H2O2 generation: redox signaling and oxidative stress. J. Biol. Chem. 289 (2014), 8735–8741.
48. Singh, J., Dobrusin, E.M., Fry, D.W., Haske, T., Whitty, A., McNamara, D.J., Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases. J. Med. Chem. 40 (1997), 1130–1135.
49. Singh, J., Petter, R.C., Kluge, A.F., Targeted covalent drugs of the kinase family. Curr. Opin. Chem. Biol. 14 (2010), 475–480.
50. Sorkin, A., Duex, J.E., Quantitative analysis of endocytosis and turnover of epidermal growth factor (EGF) and EGF receptor. Curr. Protoc. Cell Biol., 15, 2010, 14.
51. Spitz, D.R., Dornfeld, K.J., Krishnan, K., Gius, D., Oxidative Stress in Cancer Biology and Therapy. In Oxidative Stress in Applied Basic Research and Clinical Practice. 2012, Humana Press.
52. Szatrowski, T.P., Nathan, C.F., Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 51 (1991), 794–798.
53. Thress, K.S., Paweletz, C.P., Felip, E., Cho, B.C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 21 (2015), 560–562.
54. Truong, T.H., Carroll, K.S., Redox regulation of epidermal growth factor receptor signaling through cysteine oxidation. Biochemistry 51 (2012), 9954–9965.
55. Truong, T.H., Carroll, K.S., Redox regulation of protein kinases. Crit. Rev. Biochem. Mol. Biol. 48 (2013), 332–356.
56. Veal, E.A., Day, A.M., Morgan, B.A., Hydrogen peroxide sensing and signaling. Mol. Cell 26 (2007), 1–14.
57. Wind, S., Schmid, M., Erhardt, J., Goeldner, R.G., Stopfer, P., Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours. Clin. Pharmacokinet. 52 (2013), 1101–1109.
58. Winterbourn, C.C., The biological chemistry of hydrogen peroxide. Methods Enzymol. 528 (2013), 3–25.
59. Woo, H.A., Yim, S.H., Shin, D.H., Kang, D., Yu, D.Y., Rhee, S.G., Inactivation of peroxiredoxin I by phosphorylation allows localized H(2)O(2) accumulation for cell signaling. Cell 140 (2010), 517–528.
60. Wood, Z.A., Poole, L.B., Karplus, P.A., Peroxiredoxin evolution and the regulation of hydrogen peroxide signaling. Science 300 (2003), 650–653.
61. Wu, P., Nielsen, T.E., Clausen, M.H., FDA-approved small-molecule kinase inhibitors. Trends Pharmacol. Sci. 36 (2015), 422–439.
62. Yang, J., Gupta, V., Carroll, K.S., Liebler, D.C., Site-specific mapping and quantification of protein S-sulphenylation in cells. Nat. Comm., 5, 2014, 4776.
63. Yun, C.H., Boggon, T.J., Li, Y., Woo, M.S., Greulich, H., Meyerson, M., Eck, M.J., Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11 (2007), 217–227.
64. Zhang, X., Gureasko, J., Shen, K., Cole, P.A., Kuriyan, J., An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125 (2006), 1137–1149.
65. Zhang, J., Yang, P.L., Gray, N.S., Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9 (2009), 28–39.
66. Zhang, F., Wang, S., Yin, L., Yang, Y., Guan, Y., Wang, W., Xu, H., Tao, N., Quantification of epidermal growth factor receptor expression level and binding kinetics on cell surfaces by surface plasmon resonance imaging. Anal. Chem. 87 (2015), 9960–9965.